Giovanni Marsicovetere

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study

Vincenzo Carnovale, Paola Iacotucci, Vito Terlizzi et al. · Journal of Clinical Medicine · 2022 · 58 citations · Full text

Medicine, Genetics, Molecular Genetics +13

Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype

Vincenzo Carnovale, Paola Iacotucci, Vito Terlizzi et al. · Respiratory Medicine · 2021 · 48 citations

Medicine, Molecular Medicine, Pharmacotherapy +13

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease

Vito Terlizzi, C. Colangelo, Giovanni Marsicovetere et al. · Genes · 2021 · 29 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Abstracts from the 23rd Italian congress of Cystic Fibrosis and the 13th National congress of Cystic Fibrosis Italian Society

Annamaria Bevivino, Alessandra Coiana, Annalisa Fogazzi et al. · ˜The œItalian Journal of Pediatrics/Italian journal of pediatrics · 2018 · 28 citations · Full text

Medicine, Infectious Diseases, Microbiology +17